Ac yyad cmk

Eight-week-old male C57BL/6 mice were purchased from Samtako (Daejeon, South Korea) and randomly divided into three groups, as follows: control (Con, n = 8), cisplatin alone (CP, n = 8), and cisplatin plus AC-YYAD-cmk (CP + YVAD, n = 8). For cisplatin treatment, mice were given a single intraperitoneal injection of cisplatin (Sigma-Aldrich, St. Louis, MO, USA; dissolved in 0.9% normal saline) at a dose of 15 mg/kg. To evaluate the effects of AC-YYAD-cmk (Cayman Chemical, Ann Arbor, MI, USA) on cisplatin-induced nephrotoxicity, mice were injected intraperitoneally with 10 mg/kg AC-YYAD-cmk for 3 days, starting 1 h prior to a single dose of cisplatin. The dose of AC-YYAD-cmk was determined based on the results of a previous study [9 (link)]. Mice were sacrificed 3 days after cisplatin injection, and blood and kidney tissue samples were collected. Mice were housed at ambient temperature (20–22°C) under a 12 h : 12 h light-dark cycle with free access to water and food. Animal care and all experimental procedures were approved and conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Catholic University of Daegu.